dimethyl 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)malonate | 554451-51-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: dimethyl 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)malonate
• 英文别名: Dimethyl 2-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]propanedioate
• CAS: 554451-51-3
• 化学式: C₁₅H₂₅NO₆
• 分子量: 315.367
• InChiKey: WXMMWLYEFPRKCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  82.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  dimethyl 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)malonate 在 sodium hydride 、 碳酸氢钠 、 肼 作用下， 以 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-α converting enzyme (TACE)

  摘要：

  Using a pyrimidine-2,4,6-trione motif as a zinc-binding group, a series of selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) was discovered. Optimization of initial lead I resulted in a potent inhibitor (51), with an IC50 of 2 nM in a porcine TACE assay. To the best of our knowledge, compound 51 and related analogues represent first examples of non-hydroxamate-based inhibitors of TACE with single digit nanomolar potency. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.09.048
• 作为产物：
  描述：

  dimethyl 2-(1-(tert-butoxycarbonyl)piperidin-4-ylidene)malonate 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 以98%的产率得到dimethyl 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)malonate
  参考文献：
  名称：

  Barbituric acid derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and/or matrix metalloproteinases

  摘要：

  本申请描述了式I的新型巴比妥酸衍生物： 1 或其药用可接受的盐或前药形式，其中A、B、L、R 1 、R 2 、R 3 、R 4 、R 5 、n、W、U、X、Y、Z、U a 、X a 、Y a 和Z a 在本规范中定义，这些衍生物可用作TNF-α转化酶（TACE）和基质金属蛋白酶（MMP）抑制剂。

  公开号：

  US20030229084A1

文献信息

• Barbituric acid derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and/or matrix metalloproteinases
  申请人：——

  公开号：US20030229084A1

  公开（公告）日：2003-12-11

  The present application describes novel barbituric acid derivatives of formula I: 1 or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, L, R 1 , R 2 , R 3 , R 4 , R 5 , n, W, U, X, Y, Z, U a , X a , Y a , and Z a are defined in the present specification, which are useful as TNF-&agr; converting enzyme (TACE) and matrix metalloproteinases (MMP) inhibitors.

  本申请描述了式I的新型巴比妥酸衍生物： 1 或其药用可接受的盐或前药形式，其中A、B、L、R 1 、R 2 、R 3 、R 4 、R 5 、n、W、U、X、Y、Z、U a 、X a 、Y a 和Z a 在本规范中定义，这些衍生物可用作TNF-α转化酶（TACE）和基质金属蛋白酶（MMP）抑制剂。
• Intermolecular Photocatalytic C–H Functionalization of Electron-Rich Heterocycles with Tertiary Alkyl Halides
  作者：Corey Stephenson、Elizabeth Swift、Theresa Williams

  DOI：10.1055/s-0035-1561320

  日期：——

  The coupling of tertiary alkyl halides with electron-rich arenes is promoted by visible-light photoredox catalysis. Tris[2-phenylpyridinato-C 2,N]iridium(III) [Ir(ppy)3] was the optimal catalyst, enabling direct reduction of the halide from the excited state, and thereby eliminating the requirement for a stoichiometric electron donor. High yields were obtained when the aromatic component was used in

  可见光光氧化还原催化促进叔烷基卤化物与富电子芳烃的偶联。三[2-苯基吡啶基-C 2,N] 铱(III) [Ir(ppy)3] 是最佳催化剂，能够直接还原激发态的卤化物，从而消除对化学计量电子供体的要求。当芳族组分使用过量时获得高产率，尽管等摩尔量仅提供略微降低的产率。该反应耐受许多官能团，包括烯丙基、酯、酰胺或氨基甲酸酯。该反应的效率已通过流动放大的证明得到提高，并且分离和表征了一种新的取代的 Ir(ppy)3 衍生物。
• Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
  申请人：Santhera Pharmaceuticals (Schweiz) AG

  公开号：EP2210885A1

  公开（公告）日：2010-07-28

  The present invention relates to substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators, in particular as melanocortin 4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cachexia induced by e.g. cancer, chronic kidney disease (CKD) or chronic heart failure (CHF), muscle wasting, anorexia induced by e.g. chemotherapy or radiotherapy, anorexia nervosa, amyotrophic lateral sclerosis (ALS), pain, neuropathic pain, anxiety and depression, nausea and emesis.

  本发明涉及取代杂环芳基哌啶衍生物作为黑色素皮质素-4受体调节剂，特别是作为黑色素皮质素-4受体拮抗剂。这些拮抗剂可用于治疗由癌症、慢性肾病（CKD）或慢性心力衰竭（CHF）引起的消瘦症、肌肉消耗、由化疗或放疗引起的厌食症、神经性厌食症、肌萎缩侧索硬化症（ALS）、疼痛、神经性疼痛、焦虑和抑郁症、恶心和呕吐等疾病和疾病的治疗。
• BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES
  申请人：Duan Jingwu

  公开号：US20070167451A1

  公开（公告）日：2007-07-19

  The present application describes novel barbituric acid derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, L, R 1 , R 2 , R 3 , R 4 , R 5 , n, W, U, X, Y, Z, U a , X a , Y a , and Z a are defined in the present specification, which are useful as TNF-α converting enzyme (TACE) and matrix metalloproteinases (MMP) inhibitors.

  本申请描述了新型的巴比妥酸衍生物式I：或其药物可接受的盐或前药形式，其中A、B、L、R1、R2、R3、R4、R5、n、W、U、X、Y、Z、Ua、Xa、Ya和Za在本说明书中有定义，它们可用作TNF-α转化酶（TACE）和基质金属蛋白酶（MMP）抑制剂。
• Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators
  申请人：Henneböhle Marco

  公开号：US20100249093A1

  公开（公告）日：2010-09-30

  The present invention relates to substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amyotrophic lateral sclerosis (ALS), anxiety and depression. Generally all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.

  本发明涉及取代杂环基哌啶衍生物作为黑色素-4受体调节剂。根据化合物的结构和立体化学，本发明的化合物可以是人类黑色素-4受体（MC-4R）的选择性激动剂或选择性拮抗剂。激动剂可用于治疗肥胖症、糖尿病和性功能障碍等疾病和疾病，而拮抗剂可用于治疗癌症消耗症、肌肉萎缩、厌食症、肌萎缩侧索硬化症（ALS）、焦虑和抑郁症等疾病和疾病。通常，涉及MC-4R调节的所有疾病和疾病都可以用本发明的化合物治疗。